Business
Isodiol International Inc. Outlines Strategy for Balanced, Long-Term Growth to Increase Shareholder Value
Isodiol International Inc. Outlines Strategy for Balanced, Long-Term Growth to Increase Shareholder Value.
About this update from Isodiol International Inc
[{"type":"text","content":"\nIsodiol further aligns its business strategies around core competencies and expands its sales force globally to capitalize on the untapped market for its registered Active Pharmaceutical Ingredient (API), CBD extracts, and contract manufacturing capabilities.\n VANCOUVER, British Columbia, June 29, 2018 (GLOBE NEWSWIRE) --  Isodiol International Inc. (CSE: ISOL) (OTCQB:ISOLF) (FSE: LB6A.F) (the “Company” or “Isodiol”), a global CBD innovator and market leader, announces plans to pursue a focused business strategy designed to improve its market leadership and fully leverage the potential of recent acquisitions.  “Over the past 6 months, we made significant investments that built a diverse foundation for the Company through acquisitions, and we are now shifting our focus to optimally operating our various business segments.  Specifically, we are leveraging these recent acquisitions to scale up and maximize the growth of the Company, while taking advantage of developing opportunities that are arising from positive changes in regulations that affect hemp and CBD around the globe,” said the Company’s CEO, Marcos Agramont. To give effect to these initiatives, the Company is sharpening its focus on three core business strategies designed to increase shareholder value through primary Business to Business (B2B) revenues and secondary retail revenues. Nutraceutical, Pharmaceutical, and Clinical Supply of CBD Ingredients The Company is an industry leader in CBD, supplying the market with CBD extracts in four categories:  NUTRA99: A nutraceutical-grade CBD isolate derived from US Farm Bill Compliant hemp.ISO99: A proprietary extracted nutraceutical-grade CBD isolate derived from EU organic certified hemp.Spectreus: A full-spectrum hemp oil extract derived from US Farm Bill Compliant hemp.BSPG API:  An MHRA (The Medicines and Healthcare Regulatory Agency) registered Active Pharmaceutical Ingredient (API) for use in clinical trials and for formulation of Finished Pharmaceutical Products (FPPs). As of today, the Company is able to sell its API as a regulatorily compliant import into Canada to Licensed Dealers (LDs) and for use in the manufacture of approved consumer products by Licensed Producers (LPs). This is a significant accomplishment that places the Company at the ...